RASAL1 and chronic kidney disease: In two CKD patients who were newly put on Dihydralazine medication due to therapy-resistant arterial HTN (Supplementary Table F), we observed decreased levels of circulating RASAL1 promoter DNA fragments within one week of Dihydralazine treatment (Fig. 10F), providing evidence that lower levels of circulating RASAL1 promoter DNA fragments in the Dihydralazine group were a direct reflection of Dihydralazine's de-methylating activity.